Provided by Tiger Trade Technology Pte. Ltd.

ENGENE HOLDINGS INC

1.87
+0.06003.31%
Volume:730.51K
Turnover:1.36M
Market Cap:125.26M
PE:-0.88
High:1.89
Open:1.85
Low:1.82
Close:1.81
52wk High:12.25
52wk Low:1.40
Shares:66.98M
Float Shares:32.73M
Volume Ratio:3.70
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1229
EPS(LYR):-2.2947
ROE:-52.58%
ROA:-28.86%
PB:0.49
PE(LYR):-0.81

Loading ...

enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
May 29

enGene Holdings Is Maintained at Neutral by UBS

Dow Jones
·
May 15

enGene price target lowered to $2 from $9 at UBS

TIPRANKS
·
May 14

UBS Adjusts enGene Price Target to $2 From $9, Maintains Neutral Rating

MT Newswires Live
·
May 14

enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed

Simply Wall St.
·
May 09

enGene Therapeutics announces annual shareholder meeting webcast

Reuters
·
May 09

Citizens Downgrades enGene to Market Perform From Market Outperform

MT Newswires Live
·
May 08

Piper Sandler Downgrades enGene Holdings to Neutral From Overweight, Adjusts Price Target to $4 From $7

MT Newswires Live
·
May 08

enGene Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 08

enGene Holdings (ENGN) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 08

enGene Therapeutics Inc. : Wells Fargo Cuts Target Price to $2 From $25

THOMSON REUTERS
·
May 08

enGene Holdings Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
May 08

enGene downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
May 08

enGene Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $4 From $7

THOMSON REUTERS
·
May 08

enGene downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
May 08

enGene announces updated interim results from LEGEND cohort

TIPRANKS
·
May 07

EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint

Dow Jones
·
May 07

enGene reports 43% six-month complete response in Phase 2 LEGEND bladder cancer trial

Reuters
·
May 07

enGene Therapeutics Inc - Detaimigene Achieves 54% Complete Response at Any Time, 43% at Six Months as of April 21, 2026

THOMSON REUTERS
·
May 07

enGene Therapeutics Inc - 2.4% Experienced Treatment Interruption, 2.4% Discontinuation Due to Adverse Events

THOMSON REUTERS
·
May 07